medigraphic.com
SPANISH

Revista ADM Órgano Oficial de la Asociación Dental Mexicana

ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2020, Number 3

<< Back Next >>

Rev ADM 2020; 77 (3)

Overview, management, care and clinical manifestations of SARS-CoV-2

Orellana-Centeno JE, Morales-Castillo V, Guerrero SRN
Full text How to cite this article 10.35366/94009

DOI

DOI: 10.35366/94009
URL: https://dx.doi.org/10.35366/94009

Language: Spanish
References: 16
Page: 153-155
PDF size: 140.85 Kb.


Key words:

COVID 19, public health, oral clinical manifestations.

ABSTRACT

Studies are ongoing to describe the clinical symptoms of COVID-19, and fever, shortness of breath, dry cough, fatigue, diarrea, and some other less common ones that have been reported are already documented at a general or systemic level. Symptomatology occurs at different stages ranging from asymptomatic to severe and critical. With an incubation period of up to fourteen days and with an average of six days, which is the most common moment of presence of signs and symptoms. Some of the oral manifestations present are: Loss of taste sensation (ageusia), absence of olfaction, dry mouth.


REFERENCES

  1. Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med. 2020; 201 (4): P7-P8. doi: 10.1164/rccm.2014P7.

  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506. doi: 10.1016/S0140-6736(20)30183-5.

  3. Kohn WG, Collins AS, Cleveland JL, Harte JA, Eklund KJ, Malvitz DM; Centers for Disease Control and Prevention. 2003. Guidelines for infection control in dental health-care settings-2003. Available in: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5217a1.htm.

  4. American Dental Association 2020b. ADA interim guidance for minimizing risk of COVID-19. Available in: transmission.https://www.ada.org/~/media/CPS/Files/COVID/ADA_COVID_Int_Guidance_Treat_Pts.pdf?utm_source=cpsorg&utm_medium=covid-cps=virus-lp&utm_content=cv-pm-ebd-interim-response&utm_campaign=covid-19

  5. Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig. 2020; 24 (4): 1619-1621. doi: 10.1007/s00784-020-03248-x.

  6. Dziedzic A, Wojtyczka R. The impact of coronavirus infectious disease 19 (COVID-19) on oral health [published online ahead of print, 2020 Apr 18]. Oral Dis. 2020; 10.1111/odi.13359. doi: 10.1111/odi.13359.

  7. Samaranayake LP, Reid J, Evans D. The efficacy of rubber dam isolation in reducing atmospheric bacterial contamination. ASDC J Dent Child. 1989; 56 (6): 442-444.

  8. Mallineni SK, Innes NP, Raggio DP, Araujo MP, Robertson MD, Jayaraman J. Coronavirus disease (COVID-19): characteristics in children and considerations for dentists providing their care. Int J Paediatr Dent. 2020; 30: 245-250. doi: 10.1111/ipd.12653.

  9. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004; 59: 252-256. doi: 10.1136/thorax.2003.012658.

  10. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14 (1): 58-60. doi: 10.5582/ddt.2020.01012.

  11. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14 (1): 72-73. doi: 10.5582/bst.2020.01047.

  12. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020; 181 (4): 905-913.e7. doi: 10.1016/j.cell.2020.04.004.

  13. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020; 10.1001/jama.2020.2648. doi: 10.1001/jama.2020.2648.

  14. Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M et al. Histopathologic changes and SARS–CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. 2020; M20-0533. doi: 10.7326/M20-0533.

  15. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395: 514-523. doi: 10.1016/S0140-6736(20)30154-9.

  16. Bi Q, Wu Y, Mei S et al. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. Med Rxiv. 2020. Available in: https://doi.org/10.1101/2020.03.03.20028423




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev ADM. 2020;77